Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Systematic review of the perioperative immunotherapy in patients with non-small cell lung cancer: evidence mapping and synthesis.Frontiers in oncology · 2023
   Pooled it
2. Plasma proteomics predicts pathological complete response and reveals LIF as a potential mediator of resistance to neoadjuvant immunochemotherapy in resectable NSCLC.Journal for immunotherapy of cancer · 2026
   Article
3. Progress in perioperative immunotherapy for lung cancer and analysis of therapy (Review).Oncology letters · 2026
   Review
4. Uniportal video-assisted thoracoscopic surgery does not increase recurrence rates following pneumonectomy in non-small cell lung cancer: a retrospective study from the National Cancer Center of China.Translational lung cancer research · 2025
   Article
5. Dynamics of tertiary lymphoid structures and immune cross talk in early versus advanced colorectal cancer: potential implications for immunotherapy.Cancer immunology, immunotherapy : CII · 2025
   Article
6. AMPK-dependent Parkin activation suppresses macrophage antigen presentation to promote tumor progression.Science advances · 2025
   Article
7. The effect of baseline versus early glucocorticoid use on immune checkpoint inhibitor efficacy in patients with advanced NSCLC.Frontiers in oncology · 2025
   Article
8. Prospects for the application of pathological response rate in neoadjuvant therapy for gastric cancer.Frontiers in oncology · 2025
   Review
9. Unveiling ficolins: diagnostic and prognostic biomarkers linked to the Tumor Microenvironment in Lung Cancer.World journal of surgical oncology · 2024
   Article
10. Modulation of T Cell Differentiation in Mice with COPD Combined with Lung Cancer Through Key Targets of PD-1 by Tao Hong Si Wu Tang.Applied biochemistry and biotechnology · 2024
    Article
11. Long-term complete response to anti-programmed-death-1 monotherapy in a patient with relapsed and refractory ovarian adenocarcinoma: A case report.World journal of clinical cases · 2024
    Article
12. Development of postoperative bronchopleural fistula after neoadjuvant immunochemotherapy in non-small cell lung cancer: case reports and review of the literature.Journal of cancer research and clinical oncology · 2024
    Review
13. Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.Nature reviews. Clinical oncology · 2024
    Review
14. Identification and Validation of T-Cell Exhaustion Signature for Predicting Prognosis and Immune Response in Pancreatic Cancer by Integrated Analysis of Single-Cell and Bulk RNA Sequencing Data.Diagnostics (Basel, Switzerland) · 2024
    Article
15. Current status and prospect of immunotherapy for colorectal cancer.International journal of colorectal disease · 2023
    Review
16. Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies.MedComm · 2023
    Review
17. Multidirectional characterization of cellular composition and spatial architecture in human multiple primary lung cancers.Cell death & disease · 2023
    Article
18. Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancer.Cancer science · 2023
    Article
19. Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC).Frontiers in oncology · 2023
    Article
20. Predicting Tumor Mutation Burden andJournal of personalized medicine · 2022
    Article

Corrections and comments

• Commented on by
  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.2018
• Comment on
  Neoadjuvant PD-1 Blockade in Resectable Lung Cancer.2018

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as